meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
encorafenib plus binimetinib
HER inhibitor
HER2 inhibitor
tucatinib based treatment
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
atezolizumab plus FOLFOXIRI plus bevacizumab
avelumab based treatment
avelumab alone
dostarlimab based treatment
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs topoisomerase I inhibitor
vs irinotecan
vs FOLFIRI(5FU/irinotecan)
vs Standard of Care (SoC)
vs non active control
vs BSC
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs Bevacizumab plus FOLFOXIRI
vs regorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network